FOR IMMEDIATE RELEASE
October 24, 2018
CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019
- CritiTech Particle Engineering Solutions was selected as only one of twenty organizations to present a Lightning Talk at the 2019 Annual Biomedical Advanced Research and Development Authority (“BARDA”) Industry Day Conference in Washington D.C.
- CritiTech Particle Engineering Solutions presented an overview of is proprietary Supercritical Precipitation Technology, a drug development platform for producing next-generation, inhaled medical countermeasures.
CritiTech Particle Engineering Solutions announces that it was selected to present a Lightning Talk, “Next-Gen Pulmonary Medical Countermeasures Enabled by Supercritical Precipitation (SCP) Technology,” at BARDA Industry Day 2019 in Washington DC. BARDA Industry Day 2019 is a two-day conference that brings together industry, academia, and government to learn about the U.S. Government’s medical countermeasure priorities and gain exposure to certain innovations and technologies that can support those priorities.
“Being selected to present a Lighting Talk on our Supercritical Precipitation Technology at BARDA Industry Day 2019 is an honor and a great opportunity for the U.S. government and industry to learn how our Supercritical Precipitation Technology can enable next generation inhaled medical countermeasures,” said Matthew McClorey, President. “Our Supercritical Precipitation drug development platform can be a useful tool to develop more effective and safer inhaled therapeutics and antidotes that can be administered before or after exposure to chemical and biological warfare agents.”
The Supercritical Precipitation Technology has proven to be a useful tool for producing unique drug particles ideal for pulmonary delivery – particles with low bulk density, high surface area, and small physical size. It has been used to process numerous drugs, from various drug classes, with mass median aerodynamic particle sizes ideal for direct delivery into the lung.
Inhaled drugs produced with the Supercritical Precipitation Technology are delivered into the lungs at high concentrations and remain active in the lungs for increased durations with limited systemic exposure. In addition, no excipients or additives are required when producing drugs with the Supercritical Precipitation Technology, resulting in delivery of pure drug into the lungs.
Since the Supercritical Precipitation Technology is a scaled-up, validated and continuous manufacturing process, CritiTech Particle Engineering Solutions can support the development of inhaled medical countermeasures from proof of concept through commercial manufacturing.
About CritiTech Particle Engineering Solutions
CritiTech Particle Engineering Solutions (CT PES) is a rapidly-growing, multi-service, pharmaceutical Contract Development Manufacturing Organization (CDMO) and Contract Research Organization (CRO) with extensive experience and expertise in particle engineering, material characterization, analytical testing, early-stage drug development, and pre-clinical and clinical manufacturing. It uses its proprietary Supercritical Precipitation Technology and Spray Drying to help its customers improve and optimize the bioavailability of poorly soluble drugs. It also uses these technologies to engineer a wide range of pharmaceutical drugs to improve their efficacy, pharmacokinetics, dosing, delivery and toxicity.
About the Biomedical Advanced Research and Development Authority (“BARDA”)
BARDA’s mission is to develop and procure needed medical countermeasures, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures, against a broad array of public health threats, whether natural or intentional in origin.
CritiTech Particle Engineering Solutions Contact